Genflow Biosciences plc is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs.
The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.Genflow Biosciences lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. It is a recombinant self-complementary AAV containing a transgene encoding the cDNA portion of a variant of the human SIRT6 gene found in centenarians.